Quoin Pharmaceuticals, Ltd.
QNRX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.01 | 0.00 | -0.00 |
| FCF Yield | -67.90% | -56.43% | -1,842.81% | -88.41% |
| EV / EBITDA | -1.00 | -0.90 | 0.24 | -0.97 |
| Quality | ||||
| ROIC | -84.64% | -45.49% | -19.83% | 113,084.20% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.56 | 1.00 | 0.68 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -42.10% | -15.99% | -2.63% | -8.69% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | 0.27 | 0.29 | 0.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,081.17 | -2,330.72 | 0.00 | -799.12 |